Dr. Srdan Verstovsek, Dr. Ross Levine and Dr. Olatoyosi Odenike, provide details at the 2014 American Society of Clinical Oncology (ASCO) annual meeting in Chicago about the latest developments in antifibrotic agents for the treatment of myelofibrosis (MF). The experts give specific details about the promising new medication, PRM-151, as well as others that have been in recent trials such as the Hedgehog Pathway Inhibitor IPI-926.

Loading more stuff…

Hmm…it looks like things are taking a while to load. Try again?

Loading videos…